185 related articles for article (PubMed ID: 20714941)
1. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
Kim R; Aucejo F
J Gastrointest Cancer; 2011 Mar; 42(1):50-3. PubMed ID: 20714941
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
Wang Y; Speeg KV; Washburn WK; Halff G
World J Gastroenterol; 2010 Nov; 16(43):5518-22. PubMed ID: 21086573
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
4. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
Kim R; Menon N; Aucejo F
Med Oncol; 2011 Dec; 28(4):1044-7. PubMed ID: 20635167
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Matsuda Y; Ichida T; Fukumoto M
Med Mol Morphol; 2011 Sep; 44(3):117-24. PubMed ID: 21922382
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Rowe IA
Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
[No Abstract] [Full Text] [Related]
8. Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Pfeiffenberger J; Koschny R; Hoffmann K; Mehrabi A; Schmitz A; Radeleff B; Stremmel W; Schemmer P; Ganten TM
Langenbecks Arch Surg; 2013 Dec; 398(8):1123-8. PubMed ID: 24091908
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Weinmann A; Niederle IM; Koch S; Hoppe-Lotichius M; Heise M; Düber C; Schuchmann M; Otto G; Galle PR; Wörns MA
Dig Liver Dis; 2012 May; 44(5):432-7. PubMed ID: 22265328
[TBL] [Abstract][Full Text] [Related]
10. Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases.
Spada F; Squadroni M; Lorizzo K; Farris A; Fazio N
Tumori; 2012; 98(2):53e-56e. PubMed ID: 22678005
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
[TBL] [Abstract][Full Text] [Related]
12. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
Horger M; Lauer UM; Schraml C; Berg CP; Koppenhöfer U; Claussen CD; Gregor M; Bitzer M
BMC Cancer; 2009 Jun; 9():208. PubMed ID: 19558720
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Sakata K; Matsugaki S; Kajiwara M; Fukuizumi K; Tajiri N; Matsukuma N; Sakai T; Ono N; Yano Y; Koga H; Kurogi J; Takata A; Sumie S; Satani M; Yamada S; Niizeki T; Aino H; Iwamoto H; Torimura T; Sata M
Oncology; 2013; 84(2):108-14. PubMed ID: 23147476
[TBL] [Abstract][Full Text] [Related]
14. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.
Pfiffer TE; Seehofer D; Nicolaou A; Neuhaus R; Riess H; Trappe RU
Tumori; 2011; 97(4):436-41. PubMed ID: 21989430
[TBL] [Abstract][Full Text] [Related]
15. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
[TBL] [Abstract][Full Text] [Related]
16. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.
Yeganeh M; Finn RS; Saab S
Am J Transplant; 2009 Dec; 9(12):2851-4. PubMed ID: 20021481
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.
Teng CL; Hwang WL; Chen YJ; Chang KH; Cheng SB
World J Surg Oncol; 2012 Feb; 10():41. PubMed ID: 22339891
[TBL] [Abstract][Full Text] [Related]
19. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M
World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070
[TBL] [Abstract][Full Text] [Related]
20. 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
Siemerink EJ; Mulder NH; Brouwers AH; Hospers GA
Oncologist; 2008 Jun; 13(6):734-5; author reply 736-7. PubMed ID: 18586929
[No Abstract] [Full Text] [Related]
[Next] [New Search]